Press release

Glytec Awarded Patent Allowance for Virtual Insulin Titration in Concert with CGM, Smart Pens and Other Diabetes Technologies

Sponsored by Businesswire

the pioneer of digital therapeutics, has been awarded another patent
allowance by the United States Patent and Trademark Office (USPTO). The
latest allowance references interactions between the company’s
software-as-a-medical-device platform for insulin titration and multiple
connected diabetes technologies, including continuous glucose monitoring
(CGM) systems, smart insulin pens and insulin pumps.

“As use of CGM grows, especially for people with type 2 diabetes, the
missing element of insulin titration needs to be satisfied,” says
Glytec’s Chief Medical Officer and diabetologist, Dr.
Andrew S. Rhinehart
. “This is where Glytec enters the picture. Our
ability to seamlessly interact with glucose data that’s captured through
CGM and use it to personalize insulin therapy is how patients are going
to see real results, real improvements.”

Rhinehart adds: “Training tens of thousands of primary care providers on
how to interpret and act on CGM data is a daunting proposition. Our
platform can obviate that need, offering primary care providers the
means to use CGM data to formulate timely and discrete dosing
recommendations in a highly efficient, effective and scalable manner.”

The new USPTO patent allowance awarded to Glytec depicts the following
key systems and methods [highly abridged and consolidated]:

  • A dosing controller comprising data processing hardware in
    communication with memory hardware obtains glucose data for a patient
    from either: (A) a continuous glucose monitoring system in
    communication with a patient device, or (B) a remote computing device
    that executes a program for downloading the data from a glucometer or
    continuous glucose monitoring system. Such data includes glucose
    measurements and times associated with those measurements, among other
  • A dosing controller transmits a recommended meal bolus dose of
    insulin to a patient via: (A) an administration device (e.g., smart
    insulin pen, insulin pump or other) in communication with a patient
    device, or (B) a patient device that executes a mobile application
    configured to transmit the recommended meal bolus dose of insulin to
    an administration device. The mobile application may also be
    configured to display on a screen of the patient device the number of
    carbohydrates consumed by the patient during a selected time interval.
    Additionally, the administration device may be configured to
    automatically dial in and administer the number of units of insulin
    for the recommended meal bolus.

“A lot of new diabetes technologies have been introduced over the past
decade, but the percentage of people with type 2 diabetes who are at
goal has not improved,” says Glytec’s Senior Vice President Research &
Development, Robby
. “We believe a connected, virtual care model that capitalizes
on these new technologies and makes the data truly actionable — as
described in this latest patent allowance as well as earlier patent
allowances — will serve as a catalyst for sustained A1C reduction,
increased time in range and other outcomes improvements. CGM, smart
insulin pens and insulin pumps all play an important role, and Glytec’s
insulin titration and medication optimization capabilities are designed
to support and enhance them whether they’re being used in an outpatient
or inpatient setting.”

About Glytec

Founded in 2006, Glytec is the pioneer of digital therapeutics,
improving the lives of people with diabetes by making insulin a more
effective and accessible option for millions unable to achieve their
treatment goals. The company’s patented eGlycemic Management System®
is the only FDA-cleared software-as-a-medical-device (SaMD) platform to
enable the mass personalization of insulin across the continuum of care:
inpatient, outpatient and virtual settings alike. Glytec offers several
comprehensive programs combining evidence-based decision support
technologies with expert professional services proven to aid providers
in achieving best practices and standardization while reducing
hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost.
The company has offices in Waltham, Massachusetts and Greenville, South
Carolina. For more information visit